1. Effect of verapamil on cardiac protein kinase C activity in diabetic rats
- Author
-
Tanaka Yasushi, Ogawa Tsutomu, Abe Nanami, Ikebuchi Motoyoshi, Shigeta Yukio, Asahina Takayuki, Takagi Yoshihumi, and Kashiwagi Atsunori
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Heart Ventricles ,PKC activity ,Diabetes Mellitus, Experimental ,Basal (phylogenetics) ,Internal medicine ,Diabetes mellitus ,medicine ,Animals ,Insulin ,Protein Kinase C ,Protein kinase C ,Pharmacology ,chemistry.chemical_classification ,Membranes ,business.industry ,Myocardium ,Body Weight ,Rats, Inbred Strains ,Organ Size ,Streptozotocin ,medicine.disease ,Rats ,Cytosol ,Endocrinology ,Enzyme ,Verapamil ,chemistry ,cardiovascular system ,business ,medicine.drug - Abstract
We examined the effect of verapamil treatment on cardiac protein kinase C (PKC) activity in streptozocin-induced diabetic rats. Basal cardiac PKC activity in diabetes increased in both cytosolic (by 94%, P less than 0.01) and membrane (by 41%, P less than 0.05) fractions as compared with that in controls. Subcutaneous administration of 8 mg/kg verapamil twice a day for 8 weeks induced a significant decrease in both cytosolic (by 59%, P less than 0.01) and membrane (by 50%, P less than 0.01) PKC activity in diabetes as compared with the activity in the non-treated diabetic groups. In contrast, cardiac cytosolic PKC activity in control rats was significantly (P less than 0.01) decreased by 41% as compared with that of the non-treated control group without there being any change in membrane PKC activity. Our data demonstrate that verapamil treatment may ameliorate the abnormal activation of cardiac PKC in diabetes.
- Published
- 1991